Phil Thomson - GlaxoSmithKline Plc Senior Vice President - Global Communications
| GSKN Stock | MXN 655.00 51.98 7.35% |
President
Mr. Phil Thomson serves as President Global Affairs of the Company. Phil joined CET in 2011. He was appointed President, Global Affairs in April 2017, with specific responsibilities for the Groups strategic approach to Reputation, Corporationrationrate Responsibility, Global Health, China and Britains withdrawal from the European Union. He is responsible for our engagement with investors, media, government, key global community partners and employees. Previously, he was Senior Vice President, Communications and Government Affairs. He joined GSK as a commercial trainee in 1996. Phil is Chairman of The Whitehall Industry Group and a Board Member of the ChinaBritain Business Council. He earned his degree in English, History and Russian Studies from Durham University. since 2017.
| Tenure | 7 years |
| Phone | 44 20 8047 5000 |
| Web | https://www.gsk.com |
GlaxoSmithKline Plc Management Efficiency
The company has return on total asset (ROA) of 0.0659 % which means that it generated a profit of $0.0659 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of 0.3131 %, meaning that it generated $0.3131 on every $100 dollars invested by stockholders. GlaxoSmithKline Plc's management efficiency ratios could be used to measure how well GlaxoSmithKline Plc manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
| Showing other executives | PRESIDENT Age | ||
| Gordon Coburn | Cognizant Technology Solutions | 51 | |
| Daniel Mead | Verizon Communications | 60 | |
| Debashis Chatterjee | Cognizant Technology Solutions | 52 | |
| Dennis Zook | Costco Wholesale | 67 | |
| Sumithra Gomatam | Cognizant Technology Solutions | 50 | |
| Hans Vestberg | Verizon Communications | 58 | |
| Ramakrishna Chintamaneni | Cognizant Technology Solutions | 48 | |
| Peter Carter | Delta Air Lines | 59 | |
| Roy Chestnutt | Verizon Communications | 53 | |
| Matthew Ellis | Verizon Communications | 52 | |
| Joanne Smith | Delta Air Lines | 60 | |
| Richard Hirst | Delta Air Lines | 69 | |
| Joyce Magrini | Burlington Stores | 62 | |
| Craig Silliman | Verizon Communications | 49 | |
| Roger Gurnani | Verizon Communications | 55 | |
| Paul Jacobson | Delta Air Lines | 47 | |
| James Klauer | Costco Wholesale | 55 | |
| Douglas Schutt | Costco Wholesale | 55 | |
| Allen Shaheen | Cognizant Technology Solutions | 55 | |
| Rahul Samant | Delta Air Lines | 56 | |
| Russ Miller | Costco Wholesale | 60 | |
Management Performance
| Return On Equity | 0.31 | |||
| Return On Asset | 0.0659 |
GlaxoSmithKline plc Leadership Team
Elected by the shareholders, the GlaxoSmithKline Plc's board of directors comprises two types of representatives: GlaxoSmithKline Plc inside directors who are chosen from within the company, and outside directors, selected externally and held independent of GlaxoSmithKline. The board's role is to monitor GlaxoSmithKline Plc's management team and ensure that shareholders' interests are well served. GlaxoSmithKline Plc's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, GlaxoSmithKline Plc's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Vindi Banga, Senior Independent Non-Executive Director | ||
| Lynn Elsenhans, Independent Non-Executive Director | ||
| Luke Miels, President - Global Pharmaceuticals | ||
| Hal Barron, Chief Scientific Officer and Presidentident - R&D, Executive Director | ||
| Daniel Podolsky, Non-Executive Independent Director | ||
| Emma Walmsley, President - Consumer Healthcare Worldwide | ||
| Luc Debruyne, President - Global Vaccines | ||
| Andrew Witty, CEO, Executive Director | ||
| Brian McNamara, CEO - GSK Consumer Healthcare | ||
| Roy Anderson, Non-Executive Independent Director | ||
| Philip Hampton, Independent Non-Executive Director | ||
| Simon Dingemans, CFO, Executive Director, Member of Corporate Admin. and Transactions Committee and Member of Fin. Committee | ||
| Vivienne Cox, Non-Executive Director | ||
| Bill Louv, Senior Vice President - Core Business Services | ||
| Diana Conrad, Chief Officer | ||
| Roger Connor, President - Global Manufacturing & Supply | ||
| Abbas Hussain, President Global Pharmaceuticals | ||
| Phil Thomson, Senior Vice President - Global Communications | ||
| Judy Lewent, Non-Executive Independent Director | ||
| Hans Wijers, Independent Non-Executive Director | ||
| Shobie Ramakrishnan, Chief Officer | ||
| Sarah EltonFarr, Head Relations | ||
| Stephanie Burns, Non-Executive Independent Director | ||
| Julie Brown, Chief Officer | ||
| Moncef Slaoui, Chairman of Global Vaccines, Executive Director, Member of Corporate Admin. and Transactions Committee and Member of Fin. Committee | ||
| Urs Rohner, Non-Executive Independent Director | ||
| Marvinder Banga, Senior Non-Executive Independent Director | ||
| Deryck Maughan, Senior Independent Non-Executive Director | ||
| Jesse Goodman, Non-Executive Director | ||
| Laurie Glimcher, Non-Executive Director | ||
| Nick Hirons, Senior Vice President - Global Ethics and Compliance | ||
| Sally Jackson, VP Office | ||
| James Ford, Sr Compliance | ||
| Victoria Whyte, Company Secretary | ||
| Daniel Troy, Sr. VP and General Counsel | ||
| Shah Hussain, President - Europe, Japan & EMAP | ||
| Tony Wood, Chief Officer | ||
| Manvinder Banga, Non-Executive Director | ||
| David Redfern, Chief Strategy Officer | ||
| Patrick Vallance, President - Pharmaceuticals R&D | ||
| Stacey Cartwright, Non-Executive Independent Director | ||
| Regis Simard, President - Pharmaceutical Supply Chain | ||
| Iain Mackay, CFO - Designate, Executive Director | ||
| Karenann Terrell, Chief Digital & Technology Officer | ||
| Claire Thomas, Senior Vice President - Human Resources |
GlaxoSmithKline Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is GlaxoSmithKline Plc a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | 0.31 | |||
| Return On Asset | 0.0659 | |||
| Profit Margin | 0.51 % | |||
| Operating Margin | 0.25 % | |||
| Current Valuation | 1.79 T | |||
| Shares Outstanding | 2.05 B | |||
| Shares Owned By Insiders | 0.02 % | |||
| Shares Owned By Institutions | 14.10 % | |||
| Price To Earning | 11.33 X | |||
| Price To Book | 6.05 X |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in GlaxoSmithKline plc. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in board of governors. You can also try the Premium Stories module to follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope.
Complementary Tools for GlaxoSmithKline Stock analysis
When running GlaxoSmithKline Plc's price analysis, check to measure GlaxoSmithKline Plc's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy GlaxoSmithKline Plc is operating at the current time. Most of GlaxoSmithKline Plc's value examination focuses on studying past and present price action to predict the probability of GlaxoSmithKline Plc's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move GlaxoSmithKline Plc's price. Additionally, you may evaluate how the addition of GlaxoSmithKline Plc to your portfolios can decrease your overall portfolio volatility.
| Portfolio Manager State of the art Portfolio Manager to monitor and improve performance of your invested capital | |
| Latest Portfolios Quick portfolio dashboard that showcases your latest portfolios | |
| Companies Directory Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals | |
| Equity Valuation Check real value of public entities based on technical and fundamental data | |
| Balance Of Power Check stock momentum by analyzing Balance Of Power indicator and other technical ratios | |
| Technical Analysis Check basic technical indicators and analysis based on most latest market data | |
| Cryptocurrency Center Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency | |
| Financial Widgets Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets | |
| CEOs Directory Screen CEOs from public companies around the world | |
| Options Analysis Analyze and evaluate options and option chains as a potential hedge for your portfolios | |
| Stocks Directory Find actively traded stocks across global markets | |
| Global Correlations Find global opportunities by holding instruments from different markets | |
| Funds Screener Find actively-traded funds from around the world traded on over 30 global exchanges |